ImmunityBio (IBRX) is up 18.3%, or $1.10 to $7.12.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio Wins EU Nod for ANKTIVA Bladder Cancer Therapy
- ImmunityBio gets Anktiva marketing authorization by European Commission
- ImmunityBio holds ‘productive regulatory discussions’ with SFDA in Riyadh
- ImmunityBio call volume above normal and directionally bullish
- ImmunityBio launches ResQ215B study